Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Fineline Cube Feb 25, 2026
Company Deals

MGI Tech Sells Complete Genomics to Swiss Rockets for $50M – Divests US Unit to Mitigate Geopolitical Risks

Fineline Cube Feb 25, 2026
Company Deals

Junshi Biosciences Partners with Antengene on Cancer Combination – JS207 PD‑1/VEGF Bispecific Plus ATG‑037 CD73 Inhibitor

Fineline Cube Feb 25, 2026
Company Deals

Dartsbio Licenses PACAP Antibody DS009 to Slate Medicines – $130M Series A Fuels Global Migraine Development

Fineline Cube Feb 25, 2026
Company Deals

Henlius Licenses Serplulimab to Abbott for Emerging Markets – Expands Anti‑PD‑1 Global Footprint

Fineline Cube Feb 25, 2026
Policy / Regulatory

FDA Issues Draft Guidance on Plausible Mechanism Framework – Accelerates Approval Pathway for Individualized Genetic Therapies

Fineline Cube Feb 24, 2026
Company Drug

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Fineline Cube Feb 25, 2026
Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Fineline Cube Feb 25, 2026
Company Drug

Hengrui’s SHR4640 Accepted for NMPA Review for Gout and Hyperuricemia Treatment

Fineline Cube Jan 11, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that a market filing for...

Company Deals

Keymed Biosciences Licenses CM313 to Timberlyne Therapeutics for Global Development

Fineline Cube Jan 11, 2025

China-based Keymed Biosciences Inc. (HKG: 2162) has entered into a licensing agreement with US firm...

Company Deals

Biocytogen and SOTIO Biotech Partner on Colorectal Cancer ADC Candidate SOT109

Fineline Cube Jan 11, 2025

China-based Biocytogen (HKG: 2315) has announced an option and licensing agreement with SOTIO Biotech, allowing...

Company Deals

Novo Nordisk and Valo Health Expand Partnership to Develop Treatments for Obesity and Diabetes

Fineline Cube Jan 11, 2025

Partners Novo Nordisk (NYSE: NVO) and Valo Health have announced an expanded partnership, aiming to...

Company Deals

Immunochina Pharmaceuticals Raises Series E Funding for CAR-T Therapy IM19

Fineline Cube Jan 11, 2025

Beijing-based biotech Immunochina Pharmaceuticals has reportedly raised “hundreds of millions” of renminbi in a Series...

Company Drug

Sinogen’s SalMet-Vec Receives FDA Orphan Drug Designation for Pancreatic Cancer

Fineline Cube Jan 10, 2025

China’s oncology specialist Guangzhou Sinogen Pharmaceutical Co., Ltd. has announced receiving Orphan Drug Designation (ODD)...

Legal / IP

SynCardia’s Next-Generation Artificial Heart Granted Patent in China

Fineline Cube Jan 10, 2025

US-based SynCardia Systems, LLC., a global leader in total artificial heart technology, has announced that...

Company Deals

Zai Lab and MediLink Therapeutics Partner to Develop LRRC15 ADC Drug ZL-6201 for Solid Tumors

Fineline Cube Jan 10, 2025

On January 10, Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced a new strategic cooperation...

Company Deals

Danaher Corporation Partners with Innovaccer to Enhance Healthcare AI Solutions

Fineline Cube Jan 10, 2025

US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced an investment partnership...

Company Drug

Sanofi’s Sarclisa Meets Co-Primary Endpoints in Phase III IRAKLIA Study for Multiple Myeloma

Fineline Cube Jan 10, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY, EPA: SAN) has announced that the Phase III IRAKLIA...

Company Drug

FDA Grants Priority Review to Johnson & Johnson’s Nipocalimab for Myasthenia Gravis

Fineline Cube Jan 10, 2025

US-based Johnson & Johnson (J&J, NYSE: JNJ) has announced that the US FDA has granted...

Company Deals

Boehringer Ingelheim Licenses ADC Technology from Synaffix to Boost Portfolio

Fineline Cube Jan 10, 2025

German giant Boehringer Ingelheim has announced the licensing of antibody drug conjugate (ADC) technology from...

Company Deals

Alchemab Therapeutics Partners with Eli Lilly to Discover ALS Treatments

Fineline Cube Jan 10, 2025

UK-based Alchemab Therapeutics has formed a strategic partnership with US major Eli Lilly & Co....

Company Medical Device

Roche Gains FDA 510(k) Clearance for Roche Digital Pathology Dx with VENTANA DP 600

Fineline Cube Jan 10, 2025

Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced an additional 510(k) clearance from the...

Company Deals

TCMTech Files for IPO on Hong Kong Stock Exchange, Showcasing TCM AI Leadership

Fineline Cube Jan 10, 2025

China-based TCMTech Inc., recognized as the largest artificial intelligence (AI) empowered traditional Chinese medicine (TCM)...

Company Deals

Verdiva Bio Launches with USD 411 Million Series A Financing for Biopharma Development

Fineline Cube Jan 10, 2025

UK-based Verdiva Bio Limited has announced its launch as a clinical-stage biopharma company, backed by...

Company Deals

ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products

Fineline Cube Jan 10, 2025

Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The...

Company Deals

SciWind Bio and Verdiva Bio Partner on Global Development of Obesity Therapies

Fineline Cube Jan 10, 2025

On January 10, SciWind Bio announced a global development and commercialization license and collaboration agreement...

Company Deals

MediLink and Zai Lab Collaborate on LRRC15-Targeted ADC Drug ZL-6201

Fineline Cube Jan 10, 2025

Chinese biotechs MediLink Therapeutics (Suzhou) Co., Ltd and Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688)...

Company Drug

Bayer’s Elinzanetant Meets All Primary Endpoints in Phase III OASIS 4 Study

Fineline Cube Jan 10, 2025

Germany-based Bayer AG (ETR: BAYN) has announced that the Phase III OASIS 4 study for...

Posts pagination

1 … 190 191 192 … 626

Recent updates

  • FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen
  • Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label
  • United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential
  • Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer
  • Bio-Thera’s BAT4406F BLA Accepted by NMPA – Next‑Gen Anti‑CD20 mAb for Rare Disease NMOSD
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

FDA Approves AstraZeneca’s Calquence Plus Venetoclax for CLL/SLL – First All‑Oral Fixed‑Duration Regimen

Company Drug

Dupixent Wins FDA Approval for Allergic Fungal Rhinosinusitis – First Targeted Therapy for AFRS Expands Dupilumab Label

Company Drug

United Labs’ UBT251 Achieves 19.7% Weight Loss in Phase II – Triple‑Target GLP‑1/GIP/GCG Agonist Shows Blockbuster Potential

Company Deals

Astellas and Vir Biotechnology Partner on $1.7B+ PRO-XTEN TCE Deal – VIR-5500 Targets PSMA in Prostate Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.